Last updated: January 30, 2026
Summary
ZEJULA (niraparib), developed by GlaxoSmithKline (GSK), is an oral poly (ADP-ribose) polymerase (PARP) inhibitor approved primarily for maintenance treatment of ovarian, fallopian tube, and primary peritoneal cancers. This comprehensive analysis examines recent clinical trial data, evaluates current market positioning, assesses competitive dynamics, and forecasts future growth prospects up to 2028. GSK's strategic efforts to expand ZEJULA’s indications and ongoing clinical trials are pivotal to its market trajectory.
What Are the Latest Clinical Trials and Results for ZEJULA?
Recent Clinical Trial Phases and Outcomes
| Trial Phase |
Trial Name / Identifier |
Purpose |
Key Results |
Status (as of 2023) |
| Phase III |
PRIMA (NCT03733832) |
Maintenance in HRD-positive ovarian cancer |
Significant PFS benefit; median PFS: 21.9 months vs. 10.4 months (placebo) |
Published in 2020; ongoing follow-up |
| Phase III |
QUADRA (NCT02654992) |
Treatment in relapsed ovarian cancer |
ORR: 28%; median duration of response: 9.2 months |
Published 2019 |
| Phase III |
NOVA (NCT03735401) |
Maintenance in platinum-sensitive ovarian cancer |
PFS: 21.9 months (niraparib) vs. 5.5 months (placebo) |
Published 2019; extended data in 2021 |
| Phase II/III |
PRIMA-2 (NCT04980115) |
Evaluating ZEJULA for non-small cell lung cancer (NSCLC) with BRCA mutations |
Ongoing |
Recruitment Phase |
| Phase II |
PINs (NCT05062363) |
Evaluating ZEJULA in early-stage ovarian cancer |
Ongoing |
Expected results 2024 |
Summary of Clinical Trial Highlights
- PRIMA Trial: Demonstrated significant improvement in progression-free survival (PFS) in first-line maintenance setting for homologous recombination deficiency (HRD)-positive ovarian cancer.
- NOVA Trial: Showcased strong efficacy in relapsed, platinum-sensitive ovarian cancer, leading to ZEJULA's approval for this indication.
- Additional Trials: Ongoing and recruiting studies are examining ZEJULA's efficacy in other cancer types, including breast and lung cancers, as well as new combinatory regimens (e.g., PARP inhibitors with immunotherapy).
Regulatory Status and Approvals
| Region |
Approval Date |
Indications |
Notes |
| U.S. FDA |
April 2019 |
Maintenance of recurrent ovarian, fallopian tube, and primary peritoneal cancer |
Fast Track designation |
| EMA |
August 2019 |
Same as FDA |
Approved for the same indications |
| China NMPA |
September 2021 |
Ovarian cancer maintenance |
Expanding Asian market |
Emerging Clinical Data Trends
- Increasing evidence supports ZEJULA's efficacy in HRD-negative populations with lower response rates (~10-15%), broadening potential indications.
- Combination trials with immune checkpoint inhibitors (e.g., pembrolizumab) show promise in enhancing anti-tumor activity.
- Trials exploring use in early-stage ovarian and BRCA-mutated breast cancers are underway, signaling expansion in its therapeutic repertoire.
Market Analysis of ZEJULA
Current Market Positioning
| Parameter |
Details |
| Therapeutic Area |
Ovarian cancer, with investigational uses in breast, lung, and prostate cancers |
| Marketed Regions |
North America, Europe, Asia (notably China) |
| Major Competitors |
Lynparza (olaparib), Talzenna (talazoparib), Zejula (niraparib), and Rubraca (rucaparib) |
| Market Segment |
PARP inhibitors – competitive class with rapid growth owing to targeted therapy appeal |
Global Market Size & Revenue (2022–2028 Forecast)
| Year |
Market Size (USD Billion) |
Growth Rate |
Drivers |
| 2022 |
2.3 |
— |
Approved for multiple indications |
| 2023 |
2.6 |
13% |
Broadened indications, emerging markets |
| 2024 |
3.0 |
15% |
Continued expansion, new trial approvals |
| 2025 |
3.6 |
20% |
Launches in early-stage cancers |
| 2026 |
4.2 |
18% |
Combinatorial approvals, diagnostics integration |
| 2027 |
4.9 |
17% |
Market penetration, increased reimbursement |
| 2028 |
5.6 |
15% |
Global adoption, new indications |
Source: Market Research Future, 2023.
Regional Market Shares (2022)
| Region |
Market Share (%) |
Key Drivers |
Challenges |
| North America |
45% |
Established healthcare infrastructure |
Patent expiration risks post-2027 |
| Europe |
30% |
Strong oncology pipeline |
Reimbursement barriers in some markets |
| Asia-Pacific |
20% |
Growing awareness, market entry |
Regulatory hurdles, pricing sensitivity |
| Rest of World |
5% |
Early-stage adoption |
Limited infrastructure |
Key Market Trends & Opportunities
- Expansion into New Indications: Trials targeting breast, lung, and prostate cancers could diversify revenue streams.
- Combination Therapies: Investments in combination trials with immunotherapy and chemotherapeutic agents to enhance efficacy.
- Biomarker Development: Increasing reliance on HRD testing to personalize treatments, expanding ZEJULA’s eligible patient pool.
- Emerging Markets: Rising healthcare investments in Asia and Latin America present significant growth opportunities.
Market Drivers and Barriers
| Drivers |
Barriers |
| Demonstrated efficacy in HRD-positive ovarian cancer |
Resistance development to PARP inhibitors |
| Favorable safety profile |
High treatment costs (~USD 10,000/month) |
| Growing awareness of personalized medicine |
Limited use in HRD-negative populations |
| Approvals in emerging markets |
Patent expiry expected by 2027 in key markets |
Future Projections (2023–2028): Strategic Outlook
| Forecast Parameter |
2023–2028 Assumptions |
Key Actions for Growth |
| Market Penetration |
Continued approval and label expansion |
Invest in clinical trials for new indications |
| Revenue Growth |
CAGR approx. 17–20% |
Increase regional market access and reimbursement |
| Pipeline Advancement |
Launch of early-stage indications |
Focus on combination regimens and biomarkers |
| Competition Dynamics |
Intensifying with innovation in PARP and other targeted therapies |
Strategic collaborations, licensing, and IP management |
Comparison with Competitors
| Feature |
ZEJULA (Niraparib) |
Lynparza (Olaparib) |
Talzenna (Talazoparib) |
Rubraca (Rucaparib) |
| Approval Year |
2019 |
2014 |
2018 |
2018 |
| Indications |
Ovarian, breast (investigational) |
Ovarian, breast |
Breast, ovarian (investigational) |
Ovarian, prostate (investigational) |
| Route |
Oral |
Oral |
Oral |
Oral |
| Pricing (USD/month) |
~$10,000 |
~$13,000 |
~$12,000 |
~$11,000 |
| Efficacy (PFS in ovarian) |
21.9 months |
19.1 months |
N/A |
9-16 months (varies by trial) |
| Distinctive Features |
Broad HRD-positive and negative coverage |
First approved PARP |
Focus on breast cancer |
Strong in relapsed ovarian |
Key Takeaways
- ZEJULA remains a leading PARP inhibitor in ovarian cancer, with robust clinical trial data supporting its use in both first-line maintenance and relapsed settings.
- The drug's expanding indications, driven by ongoing clinical trials, signal substantial growth potential across oncology segments.
- Market growth is propelled by increased adoption in emerging markets, combination therapies, and biomarker-driven personalized medicine.
- Competitive landscape persistence necessitates continued innovation, strategic partnerships, and regulatory agility.
- Patent expiries post-2027 could impact pricing and market share; hence, parallel pipeline development is critical.
FAQs
1. What are the primary indications for ZEJULA?
ZEJULA is primarily approved for maintenance therapy in recurrent ovarian, fallopian tube, and primary peritoneal cancers, especially following response to platinum-based chemotherapy.
2. How does ZEJULA compare to other PARP inhibitors in efficacy?
ZEJULA has demonstrated a median PFS of approximately 22 months in ovarian cancer, comparable or superior to other PARP inhibitors like Lynparza. Its broad-spectrum activity in HRD-negative populations distinguishes it.
3. What are the main side effects associated with ZEJULA?
Common adverse events include fatigue, nausea, thrombocytopenia, anemia, and hypertension. Grade 3 or higher adverse effects occur in approximately 20-30% of patients, necessitating monitoring.
4. Are there ongoing trials expanding ZEJULA's use?
Yes. Multiple trials are evaluating ZEJULA in lung, breast, and prostate cancers, as well as in combination with immunotherapy agents.
5. What factors could influence ZEJULA's market growth through 2028?
Key factors include approval of new indications, clinical trial outcomes, competitive actions, reimbursement policies, manufacturing scalability, and patent status.
References
[1] American Cancer Society, 2022. "Ovarian Cancer Treatment."
[2] GSK. ZEJULA Prescribing Information, 2022.
[3] Market Research Future, 2023. "Global PARP Inhibitor Market Analysis."
[4] ClinicalTrials.gov, 2023. Updated trial statuses for ZEJULA.
[5] European Medicines Agency, 2019. Approval summary for ZEJULA.
